Aims-To assess whether the overexpression of five dominant oncogene encoded proteins is crucial to the pathogenesis of ovarian carcinoma and whether this provides any useful prognostic information.
mas. The levels of expression of ILGFR 1, EGFR, c-erbB-2 and c-ras were significantly higher in the tumours of patients with recurrent or persistent disease after chemotherapy than in the tumours of patients at initial presentation (p < 0.02).
Multivariate analysis showed that residual tumour (p < 0.001), FIGO stage (p = 0'002), EGFR overexpression (p = 0030) and previous chemotherapy (p = 0.034) were independent variables for predicting survival. Conclusions-Overexpression of these oncoproteins only occurs in a small proportion of ovarian carcinomas but may have an important role in the progression of the disease. Recent insight into the molecular biology of cancer raises the hypothesis that carcinogenesis can be explained by a complex multistep process of activation of oncogenes and inactivation of tumour suppressor genes, these events acting synergistically to produce the malignant phenotype.' Alterations in the expression of oncogenes and antioncogenes, caused by mutation, rearrangement or gene amplification, or altered gene transcription, can occur spontaneously or be induced by carcinogens.23 Although for some tumour types (such as colonic carcinoma) the cascade of tumourigenic events is on the verge of being revealed, the molecular biology of epithelial ovarian cancer remains an enigma.4
In this study the expression of five dominant oncogene-encoded proteins-insulin-like growth factor I receptor (ILGFR I), epidermal growth factor receptor (EGFR), and the c-erbB-2, c-ras and c-myc products-was measured by multiparameter flow cytometry in 80 patients with ovarian carcinoma. The investigation aimed to assess whether overexpression of these oncoproteins has a crucial role in the pathogenesis of the Samples were analysed as a batch. Cryopreserved tissue blocks were thawed rapidly and disaggregated mechanically, as described before." 15 16 The resulting cell suspension was filtered through a 35 ,um nylon mesh and divided into seven samples containing about 2-5-5 105 cells each, which were spun down. A cytospin preparation was made from the first sample, which was used as a cytological control. Only tumour samples that contained more than 50% of tumour cells were included for further analysis; this resulted in the exclusion of six of the original 86 patients. The five other aliquots were incubated for one hour with the primary antibody raised against EGFR (50 ug/ml), c-erbB-2
(1/250), c-myc (1/20), pan-ras (20 pg/ml) and IGF-1 (20 ,ul/ml), respectively.'6 The pellet of the seventh aliquot was resuspended in phosphate buffered saline and served as a background fluorescence control.'5 The optimal staining technique was identified by performing a checkerboard titration of the primary and secondary antibody, optimising the incubation times and volumes and the number of washes. '7 Labelling the primary antibody with FITC conjugated rabbit anti-mouse IgG and the staining the DNA was performed, as described before. '6 The cells were analysed simultaneously for DNA and oncoprotein in the Cambridge MRC custom-built dual laser flow cytometer. Excitation, optical filtration, calibration, setup of the flow cytometer, data collection, data processing and data analysis have been given in detail elsewhere.8 16 17 Cross-blocking assays were carried out using the NEU3 peptide used as the immunogen. Cultured cells known to express high oncoprotein concentrations were used as positive controls: A431 cells (EGFR), SKBRIII (c-erbB-2), NIH3T3 EC8 16 (Ha-ras), and COL0320 HSR (c-myc [1986] [1987] [1988] [1989] , no significant differences were found. This suggests that there was no major time dependent deterioration of the measured proteins during storage of the biopsy specimens at -70°C.
Overexpression (defined as protein concentrations exceeding the 97th centile of the oncoprotein expression in the normal ovary) of c-erbB-2, c-ras, c-myc, EGFR and ILGFR I In agreement with other investigators, overexpression of one or more of the studied oncogene products could be detected in only a minority of the ovarian cancers.2'-24 Just over half of the tumours we studied had normal expression of ILGFR1, EGFR, c-erbB-2, c-ras and c-myc oncoproteins, which means that overexpression of one or more of these oncoproteins seems not to be the common molecular biological event leading to ovarian cancer. Alternatively, a small subset of malignant neoplasms might use this type of abnormal growth control. The molecular biological heterogeneity of epithelial ovarian cancer is illustrated in the present study.
It has been proposed that the hallmarks of tumour progression can probably be attributed to changes in the genes that regulate these functions, allowing sublines of the origi- 
